1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. UCB Acquires Zogenix

M&A Deal Summary

UCB Acquires Zogenix

On January 19, 2022, UCB acquired life science company Zogenix for 1.9B USD

Acquisition Highlights
  • This is UCB’s 6th transaction in the Life Science sector.
  • This is UCB’s 4th largest (disclosed) transaction.
  • This is UCB’s 7th transaction in the United States.
  • This is UCB’s 1st transaction in California.

M&A Deal Summary
Date 2022-01-19
Target Zogenix
Sector Life Science
Buyer(s) UCB
Deal Type Add-on Acquisition
Deal Value 1.9B USD
Advisor(s) BofA Securities
Leerink Partners (Financial)
Latham & Watkins (Legal)

Target

Zogenix

Emeryville, California, United States
Zogenix is a pharmaceutical company focused on the development and commercialization of medicines to treat neuroscience disorders and pain. Zogenix was founded in 2006 and is based in Emeryville, California.

Search 215,074 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

UCB

Brussels, Belgium
Category Company
Founded 1928
Sector Life Science
Employees9,000
Revenue 6.2B EUR (2024)
DESCRIPTION

UCB is a biopharma focused on severe diseases with operations in approximately 40 countries. UCB was incorporated in 1928 and is based in Brussels, Belgium.

DEAL STATS #
Overall 10 of 11
Sector: Life Science M&A 6 of 7
Type: Add-on Acquisition M&A Deals 8 of 9
State: California M&A 1 of 2
Country: United States M&A 7 of 8
Year: 2022 M&A 1 of 1
Size (of disclosed) 4 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-06-05 Engage Therapeutics

Summit, New Jersey, United States

Engage Therapeutics is a clinical stage pharmaceutical company with a deep-seated passion in epilepsy. Engage is developing Staccato® Alprazolam for the rapid termination of an active epileptic seizure.

Buy $270M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-03-04 IMIDomics

San Rafael, California, United States

IMIDomics is dedicated to the advancement of novel medicines for immune-mediated inflammatory diseases (IMIDs). IMIDomics was founded in 2015 and is based in San Rafael, California.

Buy -
Mergr

Solution for

Product

Company

Legal